Deadly brain tumors may be more vulnerable to a cutting-edge, drug-delivery technique than doctors had dared hope, according to new research from the University of Virginia. Scientists at UVA Health’s Focused Ultrasound Cancer Immunotherapy Center have found that gliomas—the most common primary brain tumors in adults—may actually be easier to treat with sound-wave-based drug delivery than healthy brain tissue is. The discovery eases some fears that tumors might resist one of the most promising new tools in brain cancer treatment. How Findings Could Reshape Clinical Trials Richard J. Price, co-director of the center and lead author of the study, told Newsweek the results carry real weight for patients. “Our findings have the potential to make a real difference for a couple of reasons,” Price said. “First, they will allow us to better understand how different types of existing brain tumor therapies stand to benefit from improved delivery to tumors with focused ultrasound. “This knowledge will, in turn, allow us to prioritize certain clinical trials and trial designs.” He added that the work also points toward the future: “Looking farther into the future, these findings will help us design entirely new drug and gene therapies that are specifically designed to work optimally with focused ultrasound.” Gliomas include glioblastoma, the deadliest form of brain cancer. Despite treatments that can extend survival and quality of life, glioblastoma is almost always fatal within five to 10 years and has devastated countless families. More than 10,000 people die from it every year in the U.S. alone. Part of what makes the disease so hard to treat is the blood-brain barrier, a natural defense system that blocks harmful germs and toxins from reaching the brain. This is designed to work on an average day but inadvertently blocks most cancer drugs in times of treatment. Doctors have long been cautious about breaching it, worried about letting in unwanted invaders along with the medicine while patients are vulnerable. Sound Waves Offer a Precise Way In Focused ultrasound offers a way around that problem. The technique uses tiny, sound-activated “microbubbles” to briefly and precisely open the blood-brain barrier, allowing drugs to pass through at an exact location—without cutting into the skull. Because cancer cells alter the structure of the blood-brain barrier inside tumors, its behavior becomes unpredictable, raising doubts about how well the ultrasound method would work in a tumor environment. Price and his team’s new study, published in Radiology, addresses those doubts directly. Beyond confirming that gliomas in laboratory mice responded well to the technique, Price’s team identified an optimal size range for drug molecules delivered this way. Very small molecules were delivered less efficiently, and very large molecules also performed worse. Medium-sized molecules worked best—though all the sizes involved remain far too small to see with the naked eye. The findings could help scientists design new drug and gene therapies built specifically to pair with focused ultrasound. The research is still in its early stages, and further studies are needed before the approach reaches patients. But the results support ongoing work at the UVA Cancer Center. Reference Price, R. J., et al. (2026). Quantitative Susceptibility Mapping Shows Size-dependent Focused Ultrasound–mediated Therapeutic Delivery to Naive Brain and Gliomas in Mice. Radiology. https://doi.org/10.1148/radiol.251005. Contact Newsweek editors on this story: Kara Dolman and Gray R. Thomas

Original source: US